Aarti Pharmalabs Limited (APL) is a leading, internationally recognized manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, synthetic caffeine, and fine chemicals.

Our Small Molecule CDMO division provides end-to-end support from Phase I through to commercial launch. We specialize in route scouting, process development, and seamless scale-up, with manufacturing capabilities ranging from kilogram batches to hundreds of metric tons.

At the core of our strategy is a commitment to sustainability and safety, evidenced by our EcoVadis Gold rating. With a robust infrastructure of seven GMP-certified manufacturing plants and three advanced R&D centers, we deliver excellence through innovation and reliability.

Key Highlights

Strategic Infrastructure: 7 manufacturing sites supported by 3 cutting-edge R&D centers.
Global Compliance: Facilities accredited by USFDA, EU GMP, EDQM, KFDA, and COFEPRIS.
Scientific Expertise: A dedicated R&D team of 300+ PhDs and Master’s- level engineers.
Proven Track Record: Successfully developed and scaled over 1,000 process chemistry steps for commercial pharma products.

Our Core Strengths

Agile and Scalable Manufacturing: A highly cost-competitive model designed for flexibility.
Advanced Technology Portfolio: Expertise in high-pressure chemistry, cryogenic reactions, and complex synthesis.
Integrated Flow Chemistry: Fully scalable solutions from lab-scale to multi-hundred-ton commercial production.
Deep Backward Integration: Capability to manage up to 20+ steps of synthesis for total supply chain security.
Future-Ready Capacity: “Plug-and-play” scalability with built-in site redundancy, supported by our recently inaugurated manufacturing plants.